Antiplatelet Therapy in Percutaneous Coronary Intervention

Wang, Tracy Y.; Rao, Sunil V.

doi:10.1016/j.iccl.2015.12.007

Cited by 9 publications

(7 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This impeded their fast recovery as they were less compliant with medication and surgical protocol. Dual antiplatelet is very important in the initial days postoperatively [13,14].…”

Section: Discussionmentioning

confidence: 99%

Outcome at Six Months After Primary Percutaneous Coronary Interventions Performed at a Rural Satellite Center of Sindh Province of Pakistan

Mujtaba¹,

Khan²,

Sohail³

et al. 2020

Cureus

View full text Add to dashboard Cite

Introduction Primary percutaneous coronary intervention (PPCI) is now a well-established treatment of acute ST-elevation myocardial infarction (STEMI). For the first time in Pakistan, various offsite satellite centers are established to perform PPCI 24-hours. Our population mainly resides in the rural area with low literacy rate and poor socioeconomic conditions. The majority of the patients who are presented in the satellite center had either never received any long-term treatment plan or were non-compliant to their medication. The objective of this study was to determine the outcome of patients at six months who underwent primary PCI at a rural satellite center of Sindh, Pakistan. Methods This study was conducted at Larkana satellite center of National Institute of Cardiovascular Diseases, Karachi. Patients who underwent PPCI for STEMI from October 2017 to March 2018 were enrolled in the study. In case of death of the patient, data were obtained from the attendant of the deceased. Patients, on follow-up visits, were interrogated for post-procedure symptoms.

show abstract

“…This impeded their fast recovery as they were less compliant with medication and surgical protocol. Dual antiplatelet is very important in the initial days postoperatively [13,14].…”

Section: Discussionmentioning

confidence: 99%

Outcome at Six Months After Primary Percutaneous Coronary Interventions Performed at a Rural Satellite Center of Sindh Province of Pakistan

Mujtaba¹,

Khan²,

Sohail³

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Dual antiplatelet therapy is very important during the initial days of PCI. 10,11 Latest Guidelines recommend that dual (mm) antiplatelet therapy should be continued for at least one-year in ACS patients. 12 At our center, we use drug-eluting stents (DES) for the primary PCI of most of the patients.…”

Section: Discussionmentioning

confidence: 99%

Antiplatelet Adherence at Six Months After Primary Percutaneous Coronary Intervention Performed at a Rural Satellite Center

et al. 2020

View full text Add to dashboard Cite

Objectives: To determine the frequency of dual antiplatelet adherence at six months after primary PCI performed at rural satellite center. Methodology: This was a descriptive study conducted at Rural Satellite Center (Larkana) of the National Institute of Cardiovascular Disease, Pakistan from October 2017 to March 2018. Patients of either gender between the ages of 20-80 years who underwent primary Percutaneous Coronary Intervention (PCI) at least six months ago were included in this study. Compliance with antiplatelet therapy was assessed by interview at follow up. Patients were labeled as compliant if they took both aspirin and clopidogrel at the time of follow up at six months. Results: Of the total of 241 patients, 208 (86.3%) were male. The mean age of the patients was 53.37 ± 11.07 years. Hypertension was present in 170 (70.5%), 101 (41.9%) were diabetic, 104 (43.2%) were smokers and 18 (7.5%) were obese. The most common culprit artery was left anterior descending (LAD) artery, 149 (61,8%), followed by the right coronary artery (RCA) in 83 (34.4%) patients. Nearly 12.1% (31) patients had the three-vessel disease, whereas, 53.9% (130) patients had single-vessel involved. Compliance with antiplatelet therapy at six months was found to be 89.6%, 219 (90.9%) were compliant to aspirin while 218 (90.5%) were compliant to clopidogrel. Conclusion: In our population, a significant number of patients (10.4%) were not compliant with dual antiplatelet therapy after six months of primary PCI. The dual antiplatelet adherence, in our population, is lower than in developed countries. Therefore, efforts should be made to increase compliance. Keywords: ACS, Aspirin, clopidogrel, Dual antiplatelet, Myocardial infarction

show abstract

“…Dual antiplatelet therapy (DAPT), through the use of a P2Y12 inhibitor, i.e. ticagrelor, prasugrel, or clopidogrel, along with aspirin, is the mainstay secondary prevention treatment of acute coronary syndrome (ACS), particularly in patients undergoing percutaneous coronary intervention (PCI) [1]. Clopidogrel is a prodrug that requires hepatic activation by cytochrome P450 (CYP), primarily CYP2C19 [2,3].…”

Section: Introductionmentioning

confidence: 99%

Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar

AlMukdad

Elewa

Arafa

et al. 2021

International Journal of Cardiology

View full text Add to dashboard Cite

Antiplatelet Therapy in Percutaneous Coronary Intervention

Cited by 9 publications

References 76 publications

Outcome at Six Months After Primary Percutaneous Coronary Interventions Performed at a Rural Satellite Center of Sindh Province of Pakistan

Outcome at Six Months After Primary Percutaneous Coronary Interventions Performed at a Rural Satellite Center of Sindh Province of Pakistan

Antiplatelet Adherence at Six Months After Primary Percutaneous Coronary Intervention Performed at a Rural Satellite Center

Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar

Contact Info

Product

Resources

About